Shahriar Zehtabchi1, Samah G Abdel Baki2, Louise Falzon3, Daniel K Nishijima4. 1. Department of Emergency Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY. Electronic address: Shahriar.zehtabchi@downstate.edu. 2. Department of Emergency Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY. Electronic address: samahabdulbaki@gmail.com. 3. Center for Behavioral Cardiovascular Health, Department of Medicine, Columbia University Medical Center, New York, NY. Electronic address: af2215@cumc.columbia.edu. 4. Department of Emergency Medicine, University of California, Davis, CA. Electronic address: daniel.nishijima@ucdmc.ucdavis.edu.
Abstract
OBJECTIVE: The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in trauma patients with severe bleeding, but its effectiveness in patients with traumatic brain injury (TBI) is unclear. We conducted a systematic review to evaluate the following research question: In ED patients with or at risk of intracranial hemorrhage (ICH) secondary to TBI, does TXA compared to placebo improve patients' outcomes? METHODS: MEDLINE, EMBASE, CINAHL, and other databases were searched for randomized controlled trial (RCT) or quasi-RCT studies that compared the effect of TXA to placebo on outcomes of TBI patients. The main outcomes of interest included mortality, neurologic function, hematoma expansion, and adverse effects. We used "Grading quality of evidence and strength of recommendations" to assess the quality of trials. Two authors independently abstracted data using a data collection form. Results from studies were pooled when appropriate. RESULTS: Of 1030 references identified through the search, 2 high-quality RCTs met inclusion criteria. The effect of TXA on mortality had a pooled relative risk of 0.64 (95% confidence interval [CI], 0.41-1.02); on unfavorable functional status, a relative risk of 0.77 (95% CI, 0.59-1.02); and on ICH progression, a relative risk of 0.76 (95% CI, 0.58-0.98). No serious adverse effects (such as thromboembolic events) associated with TXA group were reported in the included trials. CONCLUSION: Pooled results from the 2 RCTs demonstrated statistically significant reduction in ICH progression with TXA and a nonstatistically significant improvement of clinical outcomes in ED patients with TBI. Further evidence is required to support its routine use in patients with TBI.
OBJECTIVE: The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit in traumapatients with severe bleeding, but its effectiveness in patients with traumatic brain injury (TBI) is unclear. We conducted a systematic review to evaluate the following research question: In ED patients with or at risk of intracranial hemorrhage (ICH) secondary to TBI, does TXA compared to placebo improve patients' outcomes? METHODS: MEDLINE, EMBASE, CINAHL, and other databases were searched for randomized controlled trial (RCT) or quasi-RCT studies that compared the effect of TXA to placebo on outcomes of TBI patients. The main outcomes of interest included mortality, neurologic function, hematoma expansion, and adverse effects. We used "Grading quality of evidence and strength of recommendations" to assess the quality of trials. Two authors independently abstracted data using a data collection form. Results from studies were pooled when appropriate. RESULTS: Of 1030 references identified through the search, 2 high-quality RCTs met inclusion criteria. The effect of TXA on mortality had a pooled relative risk of 0.64 (95% confidence interval [CI], 0.41-1.02); on unfavorable functional status, a relative risk of 0.77 (95% CI, 0.59-1.02); and on ICH progression, a relative risk of 0.76 (95% CI, 0.58-0.98). No serious adverse effects (such as thromboembolic events) associated with TXA group were reported in the included trials. CONCLUSION: Pooled results from the 2 RCTs demonstrated statistically significant reduction in ICH progression with TXA and a nonstatistically significant improvement of clinical outcomes in ED patients with TBI. Further evidence is required to support its routine use in patients with TBI.
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn Vist; Regina Kunz; Jan Brozek; Pablo Alonso-Coello; Victor Montori; Elie A Akl; Ben Djulbegovic; Yngve Falck-Ytter; Susan L Norris; John W Williams; David Atkins; Joerg Meerpohl; Holger J Schünemann Journal: J Clin Epidemiol Date: 2011-01-19 Impact factor: 6.437
Authors: Haleema Shakur; Ian Roberts; Raúl Bautista; José Caballero; Tim Coats; Yashbir Dewan; Hesham El-Sayed; Tamar Gogichaishvili; Sanjay Gupta; Jorge Herrera; Beverley Hunt; Pius Iribhogbe; Mario Izurieta; Hussein Khamis; Edward Komolafe; María-Acelia Marrero; Jorge Mejía-Mantilla; Jaime Miranda; Carlos Morales; Oluwole Olaomi; Fatos Olldashi; Pablo Perel; Richard Peto; P V Ramana; R R Ravi; Surakrant Yutthakasemsunt Journal: Lancet Date: 2010-06-14 Impact factor: 79.321
Authors: D I Graham; I Ford; J H Adams; D Doyle; G M Teasdale; A E Lawrence; D R McLellan Journal: J Neurol Neurosurg Psychiatry Date: 1989-03 Impact factor: 10.154
Authors: Raj K Narayan; Andrew I R Maas; Franco Servadei; Brett E Skolnick; Michael N Tillinger; Lawrence F Marshall Journal: J Neurotrauma Date: 2008-06 Impact factor: 5.269
Authors: Yashbir Dewan; Edward O Komolafe; Jorge H Mejía-Mantilla; Pablo Perel; Ian Roberts; Haleema Shakur Journal: Trials Date: 2012-06-21 Impact factor: 2.279
Authors: Jonathan Marehbian; Susanne Muehlschlegel; Brian L Edlow; Holly E Hinson; David Y Hwang Journal: Neurocrit Care Date: 2017-12 Impact factor: 3.210
Authors: Simone E Dekker; Vahagn C Nikolian; Martin Sillesen; Ted Bambakidis; Patrick Schober; Hasan B Alam Journal: J Neurosci Res Date: 2017-07-25 Impact factor: 4.164
Authors: Taylor N Anderson; Holly E Hinson; Elizabeth N Dewey; Elizabeth A Rick; Martin A Schreiber; Susan E Rowell Journal: J Head Trauma Rehabil Date: 2020 Sep/Oct Impact factor: 3.117
Authors: Jason Tay; David Allan; Sara Beattie; Christopher Bredeson; Dean Fergusson; Dawn Maze; Mitchell Sabloff; Kednapa Thavorn; Alan Tinmouth Journal: BMJ Open Date: 2016-10-24 Impact factor: 2.692
Authors: Nikola Sprigg; Katie Flaherty; Jason P Appleton; Rustam Al-Shahi Salman; Daniel Bereczki; Maia Beridze; Hanne Christensen; Alfonso Ciccone; Ronan Collins; Anna Czlonkowska; Robert A Dineen; Lelia Duley; Juan Jose Egea-Guerrero; Timothy J England; Kailash Krishnan; Ann Charlotte Laska; Zhe Kang Law; Serefnur Ozturk; Stuart J Pocock; Ian Roberts; Thompson G Robinson; Christine Roffe; David Seiffge; Polly Scutt; Jegan Thanabalan; David Werring; David Whynes; Philip M Bath Journal: Lancet Date: 2018-05-16 Impact factor: 79.321